We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
H. LUNDBECK A/S (DK) PIPELINE UPDATE-FOLLOWING AN INTERIM ANALYSIS, THE STUDIES WITH BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA ARE DISCONTINUED.
- Abstract
The article reports on the joint decision between H. Lundbeck A/S and Solvay Pharmaceuticals Inc. to stop all joint research and development (R&D) activities for Solvay's compound bifeprunox in development for schizophrenia treatment. It notes that the companies' decision comes after the evaluation of recent results from an interim analysis of pooled data intended for a possible extension of the ongoing clinical phase III trial program.
- Subjects
MEDICAL research; DRUG therapy; SCHIZOPHRENIA treatment; CLINICAL drug trials; RESEARCH &; development; H. Lundbeck A/S; SOLVAY Pharmaceuticals Inc.
- Publication
Psychiatry (1550-5952), 2009, Vol 6, Issue 8, p40
- ISSN
1550-5952
- Publication type
Article